Replies to post #231314 on Biotech Values

[DewDiligence]

CARA -40%/PM on_phase-2_failure_in atopic dermatitis:

http://www.globenewswire.com/news-release/2021/04/29/2219547/29236/en/Cara-Therapeutics-Announces-Topline-Results-From-KARE-Phase-2-Dose-Ranging-Trial-of-Oral-KORSUVA-in-Atopic-Dermatitis-Patients-with-Moderate-to-Severe-Pruritus.html